Meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5) criteria for generalized anxiety disorder.
Subjects on a stable dose of an selective serotonin reuptake inhibitor (SSRI) or serotonin and noradrenaline reuptake inhibitor (SNRI) for at least 8 weeks.
Treatment-resistant - treatment resistance will be defined as lack of response to at least two drugs, from two different classes of drugs considered first-line or second-line for GAD. Only trials lasting at least 8 weeks, and with at least the minimum effective dose of the given medication will be considered failed trials.
You may not be if
Moderate to severe major depressive disorder
Moderate to high suicidality
Diagnosis of obsessive compulsive disorder (OCD), PTSD, bipolar disorder, schizophrenia, schizoaffective disorder, personality disorders, substance use disorders, intellectual disabilities and dementia or other neurological diseases including trigeminal neuralgia
Pregnant or breastfeeding women
Participants who are experiencing seizures
Implanted vagal nerve stimulation (VNS) or other electrical devices
Participants who are already undergoing transcutaneous electrical nerve stimulation
Consumption of cannabis, any cannabis by-products, illicit drugs, or alcohol above 3 drinks per week
Consumption of natural health products that may affect anxiety or depression symptoms
